Specific immunotherapy-related scleroderma. Case report

Revista Alergia Mexico

Volumn 56, Issue 4, 2009, Pages 135-144

  Morfín Maciel, Blanca María ^a   Castillo Morfín, Blanca María ^b  

^a Hospital Angeles Mocel   (Mexico)

^b UNIVERSIDAD ANÁHUAC   (Mexico)

Author keywords

Allergen specific immunotherapy; Allergic asthma; Autoimmunity; Regulatory T cells; Scleroderma

Indexed keywords

ALLERGEN; AMOXICILLIN PLUS CLAVULANIC ACID; COLLAGEN; FLUTICASONE; SALMETEROL; STEROID; TACROLIMUS;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC REACTION; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CELLULAR IMMUNITY; CHILD; DRUG WITHDRAWAL; EFFECTOR CELL; FEMALE; FRAXINUS; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; PATHOGENESIS; SCHOOL CHILD; SCLERODERMA; SKIN DEFECT; TH1 CELL; TH17 CELL; TH2 CELL; TISSUE INJURY;

EID: 77953407175     PISSN: 00025151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Tada T, Takemori T, Okumura K, Nonaka M, Tokuhisa T. Two distinct types of helper T cells involved in the secondary antibody response: independent and synergistic effects of Ia- and Ia+ helper T cells. J Exp Med 1978;147(2):446-458 (Pubitemid 8284117)
2. Borish L, Rosenwasser L. Th1/Th2 lymphocytes: doubt some more. Editorial. J Allergy Clin Immunol 1997;99(2):161-164 (Pubitemid 27091562)
3. Romagnani S. Human Th1 and Th2 doubt no more. Immunol Today 1991;12:256-257
4. Lucey DR, Clerici M, Shearer G. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic and inflammatory diseases. Clin Microbiol Review 1996;9:532-562 (Pubitemid 26366537)
5. Bettelli E, Carrier Y, Gao W, Korn T, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006;441(7090):235-238
6. Joint Task Force on Practice Parameters from the American Academy of Allergy, Asthma and Immunology. Allergen Immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007;120(3):s25-s85.
7. Rosenkranz ME, Agle LM, Efthimiou P, Lehman T. Systemic and localized scleroderma in children. Paediatr Drugs 2006;8(2):85-97.
8. Schachter RK. Localized scleroderma. Curr Opin Rheumatol 1990;2:947-955
9. Uziel Y, Krafchik BR, Silverman ED, et al. Localized scleroderma in childhood: a report of 30 cases. Semin Arthritis Rheum 1994;23:328-340 (Pubitemid 24116665)
10. Foeldvari I, Wulffraat N. Recognition and management of scleroderma in children. Paediatr Drugs 2001;3(8):575-583
11. Brasington RD, Kahl LE, Ranganathan P, et al. Immunologic rheumatic disorders. J Allergy Clin Immunol 2003;111(2):s593-s601.
12. Tablas de: Body Mass Index. Dirección URL: 〈National Institute of Health en www.nih.gov〉.
13. Romagnani S. Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res 1991;21(2):152-158
14. Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 2000;85:9-21.
15. Romagnani S. The role of lymphocytes in allergic disease. J Allergy Clin Immunol 2000;105:399-408.
16. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004;113:395-400.
17. Zhou X, Tan FK, Wang N, Xiong M, et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 2003;48(9):2585-2592 (Pubitemid 37129435)
18. Scaletti C, Vultaggio A, Maggi E, Romagnani S, Piccinni MP. Microchimerism and systemic sclerosis. Int Arch Allergy Immunol 2001;125(3):196-202.
19. Adams KM, Nelson J. Microchimerism: An investigative frontier in autoimmunity and transplantation. JAMA 2004;291:1127-1131 (Pubitemid 38541691)
20. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006;2(3):134-144
21. Postlethwaite AE, Holnes MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin. J Clin Invest 1992;90:1479-1485
22. Yazawa N, Fujimoto M, Tamaki K. Recent advances on pathogenesis and therapies in systemic sclerosis. Clin Rev Allerg Immunol 2007;33:107-112
23. Leask A. Scar wars: is TGF-β the phantom menace in scleroderma? Arthritis Res Ther 2006;8:213-219
24. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive regulators of immunity. Nature Rev 2008;8(6):478-486 (Pubitemid 351733419)
25. Mazzoni A, Siraganian RP, Leifer CA, Segal DM. Dendritic cell modulation by mast cells controls the Th1/Th2 balance in responding T cells. J Immunol 2006;177:3577-3581 (Pubitemid 44359888)
26. Mekori YA, Metcalfe DD. Mast cell-T interactions. J Allergy Clin Immunol 1999;104:517-523
27. Navi D, Saegusa J, Liu FT. Mast cells and immunological skin diseases. Clin Rev Allerg Immunol 2007;33:144-155
28. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997;18:263-266
29. Chatila TA. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 2005;116:949-959
30. Prud'homme GJ. Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007;87:1077-1091
31. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-562 (Pubitemid 38680433)
32. Huber S, Schramm C, Lehr HA, Mann A, et al. Cutting edge: TGF-β signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 2004;173(11):6526-6531
33. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-146
34. Kero J, Gissler M, Hemminki E, Isolauri E. Could Th1 and Th2 diseases coexist? Evaluation of asthma incidence in children with coeliac disease, type 1 diabetes, or rheumatoid arthritis: A register study. J Allergy Clin Immunol 2001;108:781-783 (Pubitemid 33096210)
35. Hesse M, Bayrak S, Mitchison A. Protective MHC genes and the role of IL-4 in collagen-induced arthritis. Eur J Immunol 1996;26:3234-3237
36. Balasa B, Sarvetnik N. Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for) myasthenia gravis. Immunol Today 2000;21:19-23. (Pubitemid 30410694)
37. Wakelkamp IM, Gerding MN, Van Der Meer JW, et al. Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy. Clin Exp Immunol 2000;121:453-457
38. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006;33(2):275-284 (Pubitemid 43209303)
39. Chai SK, Altman GM, Yazdanbakhsh M, Tsuji J, et al. Production of IL-10 and TGF-β in concomitant allergy and autoimmunity. Ann Allergy Asthma Immunol 2005;94:279-285
40. Banica L, Besliu A, Pistol G, Stavaru C, et al. Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 2009;42(1):41-49.
41. Akimoto S, Ishikawa O, Igarashi Y, Kurosawa M, et al. Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. Br J Dermatol 1998;138:399-406. (Pubitemid 28145504)
42. Ling EM, Smith T, Nguyen XD, et al. Relation of CD4+ CD25+ regulatory T-cell suppression of allergen-driven T cell activation to atopic status and expression of allergic disease. Lancet 2004;363:608-615 (Pubitemid 38264178)
43. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005;116:961-968 (Pubitemid 41571773)
44. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007;119(4):780-791
45. DuBuske LM. Appropriate and inappropriate use of immunotherapy. Ann Allergy Asthma Immunol 2001;87(Suppl.):56-67.
46. Position paper: immunotherapy. The European Academy of Allergology and Clinical Immunology (EAACI). Allergy 1993;48(Suppl. 14):7-35.
47. Katelaris CH, Walls RS. A study of possible ill effects from prolonged immunotherapy in treatment of allergic diseases. Ann Allergy 1984;53(3):257-261
48. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593-596
49. Wahl SM. Transforming growth factor-beta: innately bipolar. Curr Opin Immunol 2007;19:55-62.
50. Martínez-Forero I, García-Muñóz R, Martínez-Pasamar S, et al. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol 2008;38(2):576-586